TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Graft thickness (GT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: comprehension of randomization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 3/4 leukopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of grade 3/4 alopecia
Endpoint domain: Adverse events/effects
Primary endpoint: LTG serum concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfactory improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pupil diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean ring powers for Placido rings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean spherical component for the central 3.0 mm of the cornea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deltoid pain with arm movement
Endpoint domain: Adverse events/effects
Primary endpoint: Injection site redness
Endpoint domain: Adverse events/effects
Primary endpoint: Injection site swelling
Endpoint domain: Adverse events/effects
Primary endpoint: Passive knee extension range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete reversal of hindbrain herniation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional motor level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gestational age at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: functional changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient comprehension during informed consent discussions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Primary patency rate at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications in neonates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in CFQ-R RSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ramsay score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in asthma symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steroid-sparing effect of SIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 25(OH)D serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Operative intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: increase in body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MTR abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: spontaneous delivery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: adverse uterine events
Endpoint domain: Adverse events/effects
Primary endpoint: fetal acidosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Mean ratings of irritation during dust exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: month-2 culture conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Pressure Ulcers (PrUs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Alterations in TSH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevalence of TAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of NOSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of injury determined by tcMMEPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of ischemic injury of the spinal cord
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of feed intolerance
Endpoint domain: Adverse events/effects
Primary endpoint: infant difficultness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: caregivers' distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: parenting efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: End-expiratory lung volume (EELV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean spherical equivalent (SE) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean haze at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of CUI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder flexor muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck pain
Endpoint domain: Adverse events/effects
Primary endpoint: Upper back pain
Endpoint domain: Adverse events/effects
Primary endpoint: Development of macroalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Seed loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal tolerated workload during bicycle exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: typical heart failure symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CNS Objective Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Grade ≥3 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: composite cognitive score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: performance of activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: recovery of walking ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Contrast agent transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in inflammatory acne
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the concentration time curve (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percentage of dosing days resulting in an RFBM within 4 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean 24-h area under the GIR curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in ADHD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in late-phase skin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Total cholesterol to high-density lipoprotein-cholesterol (TC : HDL-C) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lifetime healthcare costs per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HF frequency and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee functional scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum AP displacement of the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative visibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sexual function parameters
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: lower leg growth rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total CAPS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: posttransplant polyglobulia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Success rate of nasolacrimal duct probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ischemic stroke equivalents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: intake of total fat, saturated fat and cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: intake of fibre, vitamin C, magnesium and potassium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to 10% T1 recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for pharmacological reversal of NMB
Endpoint domain: Adverse events/effects
Primary endpoint: Overall costs of NMB
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: satisfactory clinical response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment-related side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical success (≥15‐point improvement in ODI score; ≥20‐point improvement in VAS scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic reherniation
Endpoint domain: Adverse events/effects
Primary endpoint: Resting anal sphincter pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reducing sexual behavior risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improving HIV risk knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: increasing sexual partner conversations about HIV risk reduction
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Number of violent incidents
Endpoint domain: Adverse events/effects
Primary endpoint: mean endoscopic score at the cecum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improved FMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduced inflammatory markers (hs-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduced inflammatory markers (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduced inflammatory markers (TNF-α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PIDP (Patient-Identified Depression Prevalence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Understanding of PCA usage
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Fetal and infant death or serious infant outcome
Endpoint domain: Mortality/survival
Primary endpoint: Major maternal haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Need for dobutamine support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: freedom from adverse cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Heart rate variability (HRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of achieving therapeutic goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity of the most bothersome symptom (MBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maturation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Production of IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Production of TNF-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Production of IL-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Parents' satisfaction level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Secondary effects on body skin
Endpoint domain: Adverse events/effects
Primary endpoint: intraoperative pain/discomfort scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccination rates among healthcare workers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of febrile neutropenia (FN) episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: FEV1 AUC0‐24 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: decreased score on the temporal orientation task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction in HA/migraine days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported quality of life measures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tocolytic efficacy after 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal adverse events related to therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Early drug terminations due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Composite endpoint of death, myocardial infarction and recurrent angina
Endpoint domain: Mortality/survival
Primary endpoint: PONV frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total expenditure on LMWHs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Long-term incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term difficulty in bladder emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of disruption due to voiding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 11-deoxycortisol and deoxycorticosterone AUCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Clinical signs of heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedentary Behavior (SB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle carnosine content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Otolaryngology training examination scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative HIV incidence
Endpoint domain: Mortality/survival
Primary endpoint: Nevirapine coverage in HIV-positive cord blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antiretroviral prophylaxis coverage in seroconverters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No biochemical disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged decelerations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Fetal heart rate outcomes
Primary endpoint: Fetal heart rate accelerations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Fetal heart rate outcomes
Primary endpoint: Ephedrine usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: COPD-related acute care events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective anxiety level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: objective respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: objective heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immune responses (OPA GMTs and IgG GMCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time needed to achieve visualization of the distal common bile duct
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image quality rated by examiner
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of r16-kDa sIgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Toxicity assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in QTcF interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: neurological dysfunction rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in glucose tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: >10% weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting serum glucose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of children with IgE‐associated allergic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of children sensitized to house dust mite Dermatophagoides farinae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality of anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic requirements
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean time to operation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: high-density lipoprotein (HDL) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: insulin-like growth factor 1 (IGF-1) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Upper extremity motor improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cortisol response to naloxone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: SD of the RR intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of RR intervals with >50 msec variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: bacterial load of P. gingivalis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Persistence of anti-PRP antibody concentration > or =0.15 microg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MenC bactericidal titers > or =1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SBA-MenC titers > or =1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Participant-rated effects of benzodiazepine withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Skin temperature decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 1 RM concentric squat strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge about colorectal cancer
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: mean change in daily off time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of cases who had become pain-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LBP-related disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dialysate cancer antigen 125 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of fibroblast-dominant cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CYP2C19 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percentage of compressions delivered within an adequate rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caries prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of fentanyl consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Axial movement of IOL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Refraction stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes